Lv21
198 积分 2022-08-02 加入
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial
5小时前
求助中
The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors
1个月前
已完结
中国心血管健康与疾病报告2025概要
3个月前
已完结
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
4个月前
已完结
The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population
4个月前
已完结
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial
5个月前
已完结
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
9个月前
已完结
Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review
9个月前
已完结
Cardiovascular Risk Models Using Large-Scale Physical Examination Data
10个月前
已关闭
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
1年前
已完结
皖公网安备34019202002308
